LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

27%

73%

72 / 351 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. märts 2026, 23:01 UTC

Tulu

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises - Update

5. märts 2026, 21:54 UTC

Tulu

Costco Posts Higher 2Q Profit on Rising Sales, Membership Fees

5. märts 2026, 21:35 UTC

Suurimad hinnamuutused turgudel

ServiceNow Shares Rise After CEO Says AI Can Add Value to Software

6. märts 2026, 00:00 UTC

Uudisväärsed sündmused

Its Missile Threat Degraded, Iran Is Taking Fewer Shots at More Targets -- WSJ

5. märts 2026, 23:46 UTC

Market Talk

Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk

5. märts 2026, 23:33 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

5. märts 2026, 23:27 UTC

Market Talk

Middle East Fighting Will Prompt RBA to Delay Hike -- Market Talk

5. märts 2026, 22:54 UTC

Market Talk

Tulu

Costco Sold a $150,000 Diamond Ring in 2Q -- Market Talk

5. märts 2026, 22:50 UTC

Market Talk

Woodside Has More Exposure to Rising Gas Prices Than Santos -- Market Talk

5. märts 2026, 22:48 UTC

Tulu

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

5. märts 2026, 22:46 UTC

Tulu

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises -- Update

5. märts 2026, 22:44 UTC

Tulu

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5. märts 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. märts 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5. märts 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

5. märts 2026, 21:35 UTC

Tulu

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5. märts 2026, 21:32 UTC

Tulu

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5. märts 2026, 21:26 UTC

Tulu

These Stocks Are Today's Movers: Broadcom, Trade Desk, Berkshire Hathaway, Rigetti, Corning, Ciena, Expedia, and More -- Barrons.com

5. märts 2026, 21:24 UTC

Tulu

Costco February Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 20.8% >COST

5. märts 2026, 21:23 UTC

Tulu

Costco February Same-Store Sales Ex-Changes in Gas and Foreign Exchange Rose 7% >COST

5. märts 2026, 21:22 UTC

Tulu

Costco 2Q Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5. märts 2026, 21:21 UTC

Tulu

Costco February Digitally-Enabled Sales Rose 21.8% >COST

5. märts 2026, 21:21 UTC

Tulu

Costco Total Co Comparable Sales for February Rose 7.9% >COST

5. märts 2026, 21:20 UTC

Tulu

Costco February Net Sales Were $21.69 B >COST

5. märts 2026, 21:20 UTC

Tulu

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5. märts 2026, 21:20 UTC

Tulu

Costco Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5. märts 2026, 21:19 UTC

Tulu

Costco 2Q Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 21.7% >COST

5. märts 2026, 21:18 UTC

Tulu

Costco 2Q Digitally-Enabled Sales Rose 22.6% >COST

5. märts 2026, 21:18 UTC

Tulu

Costco 2Q Same-Store Sales Up 7.4% >COST

5. märts 2026, 21:15 UTC

Tulu

Costco 2Q EPS $4.58 >COST

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

72 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.